报价延迟最少15分钟:2026/10/19 02:36 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.69 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.10/0.04
|
|
企业价值
4.04B
|
| 资产负债 |
|
每股账面净值
1.44
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
803.79M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent. |
